Jefferies Financial Group Inc. purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 450,807 shares of the financial services provider’s stock, valued at approximately $65,083,000. iShares Biotechnology ETF comprises about 0.3% of Jefferies Financial Group Inc.’s holdings, making the stock its 20th largest holding. Jefferies Financial Group Inc. owned 1.05% of iShares Biotechnology ETF at the end of the most recent quarter.
Several other large investors have also bought and sold shares of IBB. Aster Capital Management DIFC Ltd acquired a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at $1,907,000. SG Americas Securities LLC boosted its position in shares of iShares Biotechnology ETF by 96.3% in the 3rd quarter. SG Americas Securities LLC now owns 28,569 shares of the financial services provider’s stock worth $4,125,000 after purchasing an additional 14,016 shares during the last quarter. Florin Court Capital LLP acquired a new stake in shares of iShares Biotechnology ETF during the third quarter worth $11,116,000. Viewpoint Capital Management LLC grew its stake in shares of iShares Biotechnology ETF by 1,532.1% during the third quarter. Viewpoint Capital Management LLC now owns 12,730 shares of the financial services provider’s stock worth $1,838,000 after purchasing an additional 11,950 shares during the period. Finally, Bronte Capital Management Pty Ltd. increased its holdings in iShares Biotechnology ETF by 12.6% in the second quarter. Bronte Capital Management Pty Ltd. now owns 295,346 shares of the financial services provider’s stock valued at $37,000 after purchasing an additional 32,947 shares during the last quarter. 62.45% of the stock is currently owned by institutional investors and hedge funds.
iShares Biotechnology ETF Price Performance
NASDAQ:IBB opened at $167.56 on Monday. iShares Biotechnology ETF has a 1-year low of $107.43 and a 1-year high of $179.64. The business’s 50-day moving average price is $172.68 and its two-hundred day moving average price is $161.63.
iShares Biotechnology ETF Increases Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
